420 related articles for article (PubMed ID: 16797490)
1. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
[TBL] [Abstract][Full Text] [Related]
2. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
3. [Molecular genetics of neurofibromatosis type 1].
Suzuki H; Takahashi K; Shibahara S
Nihon Rinsho; 1993 Sep; 51(9):2457-61. PubMed ID: 8411728
[TBL] [Abstract][Full Text] [Related]
4. Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging.
Su W; Xing R; Guha A; Gutmann DH; Sherman LS
Glia; 2007 May; 55(7):723-33. PubMed ID: 17348023
[TBL] [Abstract][Full Text] [Related]
5. Neurofibromin and NF1 gene analysis in composite pheochromocytoma and tumors associated with von Recklinghausen's disease.
Kimura N; Watanabe T; Fukase M; Wakita A; Noshiro T; Kimura I
Mod Pathol; 2002 Mar; 15(3):183-8. PubMed ID: 11904334
[TBL] [Abstract][Full Text] [Related]
6. Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells.
Thomas SL; Deadwyler GD; Tang J; Stubbs EB; Muir D; Hiatt KK; Clapp DW; De Vries GH
Biochem Biophys Res Commun; 2006 Sep; 348(3):971-80. PubMed ID: 16908010
[TBL] [Abstract][Full Text] [Related]
7. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.
Weiss B; Bollag G; Shannon K
Am J Med Genet; 1999 Mar; 89(1):14-22. PubMed ID: 10469432
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines.
Andersen LB; Fountain JW; Gutmann DH; Tarlé SA; Glover TW; Dracopoli NC; Housman DE; Collins FS
Nat Genet; 1993 Feb; 3(2):118-21. PubMed ID: 8499944
[TBL] [Abstract][Full Text] [Related]
9. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.
Bollag G; Clapp DW; Shih S; Adler F; Zhang YY; Thompson P; Lange BJ; Freedman MH; McCormick F; Jacks T; Shannon K
Nat Genet; 1996 Feb; 12(2):144-8. PubMed ID: 8563751
[TBL] [Abstract][Full Text] [Related]
10. NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response.
Xu J; Ismat FA; Wang T; Yang J; Epstein JA
Circulation; 2007 Nov; 116(19):2148-56. PubMed ID: 17967772
[TBL] [Abstract][Full Text] [Related]
11. Modeling neurofibromatosis type 1 tumors in the mouse for therapeutic intervention.
Parada LF; Kwon CH; Zhu Y
Cold Spring Harb Symp Quant Biol; 2005; 70():173-6. PubMed ID: 16869751
[TBL] [Abstract][Full Text] [Related]
12. Somatic deletion of the NF1 gene in a neurofibromatosis type 1-associated malignant melanoma demonstrated by digital PCR.
Rübben A; Bausch B; Nikkels A
Mol Cancer; 2006 Sep; 5():36. PubMed ID: 16961930
[TBL] [Abstract][Full Text] [Related]
13. [From gene to disease; neurofibromatosis type 1].
de Goede-Bolder A; Cnossen MH; Dooijes D; van den Ouweland AM; Niermeijer MF
Ned Tijdschr Geneeskd; 2001 Sep; 145(36):1736-8. PubMed ID: 11572174
[TBL] [Abstract][Full Text] [Related]
14. Structural and biochemical consequences of NF1 associated nontruncating mutations in the Sec14-PH module of neurofibromin.
Welti S; Kühn S; D'Angelo I; Brügger B; Kaufmann D; Scheffzek K
Hum Mutat; 2011 Feb; 32(2):191-7. PubMed ID: 21089070
[TBL] [Abstract][Full Text] [Related]
15. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.
Basu TN; Gutmann DH; Fletcher JA; Glover TW; Collins FS; Downward J
Nature; 1992 Apr; 356(6371):713-5. PubMed ID: 1570015
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells.
Mangoura D; Sun Y; Li C; Singh D; Gutmann DH; Flores A; Ahmed M; Vallianatos G
Oncogene; 2006 Feb; 25(5):735-45. PubMed ID: 16314845
[TBL] [Abstract][Full Text] [Related]
17. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation.
Roth TM; Ramamurthy P; Ebisu F; Lisak RP; Bealmear BM; Barald KF
Glia; 2007 Aug; 55(11):1123-33. PubMed ID: 17597122
[TBL] [Abstract][Full Text] [Related]
18. Tumorigenic properties of neurofibromin-deficient Schwann cells in culture and as syngrafts in Nf1 knockout mice.
Wu M; Wallace MR; Muir D
J Neurosci Res; 2005 Nov; 82(3):357-67. PubMed ID: 16180234
[TBL] [Abstract][Full Text] [Related]
19. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes.
Dasgupta B; Li W; Perry A; Gutmann DH
Cancer Res; 2005 Jan; 65(1):236-45. PubMed ID: 15665300
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH
Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
